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Abstract
Background: In 2003–2004 and 2007–2008, the regulatory banning of SSRI use in pediatrics and young adults due to
concerns regarding suicidality risk coincided with negative media coverage. SSRI use trends were analyzed from 2000–2010
in the Netherlands (NL) and the UK, and whether trend changes might be associated with media coverage of regulatory
warnings.
Methods: Monthly SSRIs sales were presented as DDDs/1000 inhabitants/day. SSRI-use trends were studied using time-
series segmented regression analyses. Timing of trend changes was compared with two periods of media coverage of
warnings. Annual Dutch SSRI prescription data were analyzed by age group.
Results: Trend changes in SSRI use largely corroborated with the periods of media coverage of warnings. British SSRI use
declined from 3.9 to 0.7 DDDs/month (95%CI 3.3;4.5 & 0.5;0.9, respectively) before the first warning period (2003–2004). A
small decrease of 20.6 DDDs/month (21.2; 20.05) was observed in Dutch SSRI use shortly after 2003–2004. From 2007–
2008, British SSRI use stabilized, whilst Dutch SSRI use diminished to 20.04 DDDs/month (20.4;0.3). Stratified analyses
showed a rapid decrease of 21.2 DDDs/month (22.1; 21.7) in UK paroxetine use before 2003–2004, but only a minimal
change in Dutch paroxetine use (20.3 DDDs/month 20.8;0.2). Other SSRI use, especially (es)citalopram, increased during
2003–2004 in both countries. Significant reductions in Dutch paroxetine use were observed in pediatrics, adolescents, and
young adults after 2003–2004.
Conclusion: Changes in SSRI use (NL & UK) were associated with the timing of the combined effect of media coverage and
regulatory warnings. Our long-term assessment illustrates that changes in SSRI use were temporal, drug-specific and more
pronounced in pediatrics and young adults. The twofold increase in SSRI use over one decade indicates that regulatory
warnings and media coverage may come and go, but they do not have a significant impact on the overall upward trend of
SSRI use as a class in both countries.
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Introduction
Health care providers and consumers alike seek health and
medical information from the news media and act accordingly,
changing their perceptions and behavior [1,2]. Several studies
have documented the effects of media and regulatory interventions
on medical decisions, health services utilization, and pharmaceu-
tical sales patterns [3,4]. The influence of news media reports or
pharmaceutical regulatory warnings for antidepressants has been
studied. For instance, Martin et al. identified a correlation between
increased negative media attention on the safety of paroxetine (a
Selective Serotonin Reuptake Inhibitor-SSRI) and the temporal
and voluntary reporting of adverse drug reactions (ADRs). The
measured decrease in paroxetine prescriptions in England, after
2002, was attributed to regulatory warnings and lawsuits (see Box
S1), rather than media reports [5]. Another study also found a
temporal decline in pediatric antidepressant prescriptions in the
United Kingdom (UK) related to regulatory actions after 2003 [6].
This regulatory-driven fall in antidepressant use in pediatrics was
also reported in a study establishing a greater impact of warnings
in the UK than in the United States (US) or the Netherlands (NL)
from 2003–2005 [7]. Volkers et al. added more evidence to this
drop in antidepressant prescriptions (2001–2005) in Dutch
pediatric patients [8]; and two other studies also showed the
influence of the warnings in the US [9,10]. However, none of
abovementioned studies analyzed the long-term influence of
regulatory warnings on antidepressant use; thus, a second set of
warnings (updates 2007–2008) were not included in those analyses.
In addition, the influence of both warning periods has not been
studied in combination with the long-term influence of media
coverage, nor has the differential impact on use in various age
groups been examined.
In a previous study, we analyzed the long-term dynamics of
‘good’ and ‘bad’ news in scientific journals and Dutch and British
newspapers in the context of the SSRIs and suicidality controversy
[21]. We found an increase in the number of articles discussing the
positive (protective) effect of antidepressants for the treatment of
depression or to prevent suicidality in scientific journals. This
‘‘positive publication tendency’’ did not influence the dissemina-
tion of negative news in Dutch and British dailies. However,
negative reporting in the same newspapers was predominantly
about the pediatric use of SSRIs and correlated with regulatory
warnings in 2003–2004 and in 2007–2008. We hypothesize that in
both the NL and the UK, the use of SSRIs was influenced by the
synergetic interaction of regulatory warnings (black box warning
and updates) and scientific and media attention to the SSRI and
suicidality controversy in 2003–2004 and 2007–2008. The aim of
this study was to specifically analyze trends of SSRI use between
January 2000 and January 2010 in the NL and the UK. In
addition, we evaluated whether trend changes could be associated
with the combined and long-term effects of the periods of intense
media coverage of the warnings. In the NL, we also analyzed the
differential impact of media coverage by the type of prescriber and
age group.
Methods
Data Source
IMS Health provided monthly antidepressant sales data in the
NL and the UK for time trends assessment on a national
(aggregated) level. Antidepressant sales data in the NL were
available from January 2000 to January 2006 for tricyclic
antidepressants (TCAs) and other antidepressants (monoamine
oxidase inhibitors (MAOIs), as well as serotonin-norepinephrine
reuptake inhibitors (SNRIs, etc.). Sales data for SSRIs were
available from January 2000 to July 2010. Antidepressant sales
data in the UK were available from January 2000 to January 2010
for all antidepressants. Escitalopram entered the market in August
2004 in the NL and in June 2002 in the UK. The sales data
provided by IMS Health consisted of wholesaler information from
ambulatory care and hospitals that cover, on average, 90% of the
total therapeutic drug sales in the NL and UK. IMS Health also
provided monthly Dutch SSRIs prescription data stratified by
specialty from January 2000 to January 2010. This dataset was
used to ascertain changes in the prescribing habits of general
practitioners (GPs), and specialists (psychiatrists, cardiologists,
oncologists, etc.). The GIP-database (Dutch insurance data
retrieved from ambulatory care; not hospitals) provided yearly
aggregate SSRI prescription data stratified by age groups from
2000 to 2010. The GIP-database covers, on average, 83% of the
insured population in the NL [22].
Data Presentation
Sales data were classified into three main groups: a) SSRIs, b)
TCAs, and c) other antidepressants (other ADs). IMS Health’s
sales data were delivered in standard counts, which is the volume
unit used to describe sales per counting unit (i.e., tablet, capsule,
etc.), together with the given concentration of the active
compound. For each antidepressant, monthly use was converted
into defined daily doses (DDD)/1000 inhabitants/day, using the
standard counts sold, dosage strength, and monthly population
estimates per country. The DDD is the international unit of drug
utilization approved by WHO for drug utilization studies and is
defined as the average maintenance dose of the studied drug when
used for its major indication in adults [23]. Yearly Dutch SSRI use
in DDD/1000/day per age groups (GIP-database) was adjusted
for the age distribution of the population. Monthly Dutch
population estimates, as well as yearly age-group population
estimates (per strata), were obtained from the Office of Statistics
Netherlands (CBS), and UK estimates from the European
Commission statistics database (Eurostat) [24,25].
Age Groups Categorization (NL only)
The age groups were defined as pediatrics (0–14 years old),
adolescents (15–19 years old), young adults (20–24 years old),
adults (25–64 years old), and elderly (65 years and older).
However, the GIP data combined the use of antidepressants for
15 to 24-year-olds between 2000–2001 hindering a differentiation
between adolescents and young adults. Therefore, the ratio of use
for adolescents and young adults in 2002–2010 was used to
extrapolate use in 2000–2001.
Periods of Intense Media Coverage of Regulatory
Warnings
Based on our analysis of scientific and newspaper coverage, we
chose the following periods of intense media coverage of
regulatory warnings: a) January 2003 to December 2004, and b)
January 2007 to December 2008. The control periods were: a)
January 2000 to December 2002, b) January 2005 to December
2006, and c) January 2009 to December 2009 [21].
Statistical Analyses
To assess whether trend changes in antidepressant use were
associated with the combined and long-term effects of both periods
of regulatory warnings and scientific and newspaper coverage, we
performed time-series analyses for overall SSRI, TCA and other
ADs use, and per specific SSRI. The algorithm that describes the
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principle of our time-series analyses based on change-points was
previously reported [26,27]. This algorithm creates segments
within the time-series under two distinct circumstances. First, each
segment is created based on the change of the slope over time by
fitting linear regressions with autoregressive (AR) models of the
second order for random error to correct for the autocorrelation of
monthly medication use over time. Second, if the average change
of the slope is similar, but there is excessive variation, then a
segment is created. The predicted values at the end of a segment
and at the beginning of the consecutive segment were fitted as
closely as possible. The segment with the lowest minimal number
of change-points was selected. Segments were created without
consideration of the periods of media coverage of regulatory
warnings; however, the selected segments were compared to
determine if they coincided with these periods.
Differences in SSRI use (mean) within Dutch age groups were
compared with an ANOVA test, assuming that the means of each
age group were equal. A Tukey HSD (honest significant
difference) post-hoc test was used to determine which age group’s
means were significantly different from one another. Statistical
significance was set at P,0.05. Analyses were performed using the
statistics software program ‘‘R’’ version 2.12.2 [28].
Results
The use of SSRIs increased in the NL from 16.7 in January
2000 to 27.9 DDDs/1000/day in July 2010, while in the UK,
SSRI use doubled from 24.7 in January 2000 to 50.1 DDDs/
1000/day in December 2009. The use of other ADs increased
from 3.3 in 2000 to 8.3 DDDs/1000/day in December 2005 in
the NL, and from 3.4 in 2000 to 12.1 DDDs/1000/day in
December 2009 in the UK. TCAs use increased from 4.2 in
January 2000 to 5.2 DDDs/1000/day in December 2005 in the
NL, whereas in the UK, TCAs use increased from 9.5 in January
2000 to 10.6 DDDs/1000/day in December 2009. On average,
the UK population used 1.5-fold more SSRIs, 1.1-fold more other
ADs, and 2.1-fold more TCAs than the Dutch did; both
populations are comparable with respect to gender and age
distributions (Table 1).
SSRI use in the NL and the UK
Regression analyses indicated a short and temporal effect of the
regulatory warnings on overall SSRI use in the NL. From 2000,
SSRI use increased in a trend that continued until November 2004
(Figure 1A+B, appendix table). After the first period of intense
media coverage of regulatory warnings, the growth trend slowed
until September 2005 when it increased again until August 2007.
SSRI use then plateaued, after the second period of intense media
coverage of the warnings and stagnated until July 2010. SSRI use
in the UK showed no negative trends during this period, with
episodes of rapid increase outside the periods of media coverage of
regulatory warnings and episodes of slowed growth during the
periods of media coverage of regulatory warnings (Figure 1A+C,
appendix table).
When analyzing individual SSRI use in the NL, citalopram and
escitalopram showed rapid growth (Figure 2A). Although the
overall increase in paroxetine use was modest (8.2 to 10.0 DDD/
1000/day), it remained the most frequently used SSRI in the NL.
Regression analysis of paroxetine use demonstrated a rapid
increase from January 2000 to May 2002, followed by a period
of slowed growth until October 2004. At the end of the first period
of media coverage of regulatory warnings, paroxetine use in the
NL decreased consistently until July 2010 (Figure 2B, appendix
table).
As in the NL, the use of citalopram and escitalopram increased
exponentially in the UK in the period under survey. Fluoxetine,
the most frequently used SSRI in the UK, demonstrated a modest
increase of 11.2 to 13.9 DDD/1000/day during the period 2000–
2010. Fluvoxamine use also demonstrated a consistent decrease
during the entire study period in the UK, as was also documented
in the NL. Overall paroxetine use decreased from 7.3 in January
2000 to 4.3 DDD/1000/day in December 2009 (Figure 2C,
appendix table). Segmented regression analysis of paroxetine use
revealed a rapid increase from January 2000 to January 2002,
followed by a rapid decrease prior to the first period of media
coverage of regulatory warnings. This downward trend persevered
until December 2009 (Figure 2D).
SSRI use in the NL Stratified by Specialty
Dutch GPs prescribed the largest share of SSRIs (mean: 80.4%,
95% CI: 80.3; 80.6, Table 2). Therefore, national SSRI use trends
and GPs’ SSRI prescribing trends were comparable (Figure 3A+B).
Segmented regression analysis demonstrated that GPs steadily
prescribed more SSRIs from January 2000 to September 2004
(appendix table). At the end of the first period of media coverage of
regulatory warnings, SSRI prescriptions by GPs slightly decreased
until January 2006 and then recovered to eventually reach a
plateau from April 2008 to December 2009. Paroxetine GP
prescriptions revealed an upward trend from January 2000 to
September 2004 (appendix table). Towards the end of the first
period of media coverage of regulatory warnings, GPs’ prescrip-
tions for paroxetine showed a negative trend and continued
Table 1. Demographics for the Netherlands and the United Kingdom (2000–2009).
Netherlands United Kingdom
Population
characteristics 2000 2009
Growth
rate (%) 2000 2009
Growth
rate (%)
Population 15,987,075 16,574,989 3.7 58,981,904 61,990,973 5.1
Gender
Female (%) 8,017,633 (50.5) 8,329,391 (50.5) 3.9 30,296,500 (50.7) 31,399,890 (50.6) 3.6
Age groups
0–20 Y 3,873,008 (24.4) 3,933,585 (23.9) 1.6 12,076,300 (20.2) 11,227,401 (18.1) 27.0
20–65 Y 9,838,500 (62.0) 10,080,387 (61.1) 2.5 38,362,500 (64.2) 40,680,109 (65.6) 6.0
.65 Y 2,152,442 (13.6) 2,471,815 (14.9) 14.8 9,316,600 (15.6) 10,083,462 (16.3) 8.2
doi:10.1371/journal.pone.0045515.t001
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decreasing until December 2009 (Figure 3C, appendix table). By
December 2009, Dutch GPs’ citalopram prescriptions were almost
level with paroxetine use (Figure 3A, appendix table). As far as
paroxetine use is concerned, we see a downward trend in specialist
prescriptions similar to the decrease in GPs’ prescriptions after the
first period of media coverage in the NL (Figure 3D). The
downward trend continued until December 2009 (Figure 3D,
appendix table) and was molecule specific. Specialists’ prescrip-
tions for Citalopram grew exponentially until the end of the first
period of media coverage of regulatory warnings. Thereafter,
growth slowed and following the second period of media coverage
of regulatory warnings Citalopram use stabilized (appendix table).
SSRI use in the NL Stratified by Age Group
In the NL, SSRI use in pediatrics, adolescents, and adults
modestly decreased after the first period of media coverage of the
warnings, and then recovered. Initially, the use of SSRIs increased
in young adults; however, by the end of the first period of media
coverage the use dropped until 2010. SSRI use by the elderly grew
during the entire study period (data not presented). Specific Dutch
SSRI trends revealed a growth in the use of citalopram,
escitalopram, and sertraline across all age groups (Figure 4A–D).
This growth was partially interrupted towards the end of the first
period of media coverage of regulatory warnings, mainly in the
younger groups (pediatrics, adolescents and young adults). The use
of fluoxetine increased; however, only in pediatrics and adoles-
cents. In adults and the elderly, the use of fluoxetine either
remained stable or decreased modestly. A constant reduction in
paroxetine use was measured prior to the first period of media
coverage of regulatory warnings (2002) in pediatrics (from 0.06 to
0.005 DDDs/1000/day), adolescents (1.9 to 0.3 DDDs/1000/
day), and young adults (6.7 to 2.2 DDDs/1000/day). Conversely,
adults used more paroxetine in the period from 2000–2004 (15.5
to 18.4 DDDs/1000/day) than after the first period of media
coverage of regulatory warnings when their use decreased to 13.5
DDDs/1000/day in 2010. A similar effect was measured in the
elderly, as paroxetine use peaked in 2004 (14.5 DDDs/1000/day)
and then decreased modestly after the first period of media
coverage of regulatory warnings to 13.3 DDD/1000/day in 2010.
Discussion
The regulatory authorities issued several warnings restricting
the use of SSRIs less than 18 years of age between 2003–2004 due
to uncertainties regarding the benefit/risk balance, and included
further restrictions for young adults (18–24-years-old) in 2007–
2008 [14–16,19]. During these years, scientific journals and Dutch
and British newspapers increased their (negative) coverage about
the SSRI and suicidality controversy [21]. We analyzed British
and Dutch SSRI use trends in 2000–2010 and assessed whether
trend changes could be associated with the combined and long-
term effect of both periods of media coverage of regulatory
warnings. To our knowledge, this is the first study that presents
such evidence on long-term use patterns of SSRIs and possible
associations with media coverage of regulatory warnings. Trend
changes in overall SSRI use largely corroborated with the periods
of media coverage of the warnings. Both post-warning periods
were associated with upward trends in SSRI use in the UK.
Contrarily, Dutch post-warning periods were associated with
limited reductions in overall SSRI use. However, these associa-
tions were not causal. In general, we found evidence of a temporal
and limited association between overall SSRI use in both countries
and both periods of media coverage of regulatory warnings. The
effect of the periods of media coverage of regulatory warnings
varied significantly per specific SSRI, country, and Dutch age
Figure 1. Antidepressant use in the NL and the UK (SSRIs, TCAs, and other antidepressants) (A), segmentation of SSRI use in the NL
(B), and in the UK (C). Dotted lines represent a change in use trend and therefore a new, or the end of a segment. *The grey periods represent the
periods of media coverage of regulatory warnings.
doi:10.1371/journal.pone.0045515.g001
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groups. Stratified analyses showed a significant decrease in
paroxetine use prior to the first period of media coverage of
regulatory warnings in the UK overall and in Dutch pediatric,
adolescent, and young adult age groups. Other SSRI use,
especially (es)citalopram, continued to increase during the first
period of media coverage of regulatory warnings in both the NL
and UK. Still, paroxetine remained the most frequently used SSRI
in the NL, whilst fluoxetine was used most frequently in UK in the
10-year period.
The present study has several strengths and limitations. The
main strengths of this paper are the long-term analysis of trends of
antidepressant use in the UK and the NL (based on national data),
the comparison between two northern European countries, and
the inclusion of all classes of antidepressants (not only those subject
to safety advisories). Although media coverage represents only one
of the many factors that may influence use (other factors might be
reimbursement systems and policies, guidelines or patient compli-
ance), our choice of the periods of media coverage of regulatory
warnings is substantiated by a systematic analysis, which is also an
important strength of the present study [21]. However, the present
study also has limitations. Two distinct types of data on SSRI use
were analyzed (IMS sales data for the NL and UK and Dutch
GIP-prescription data). None of the datasets provided information
on patient characteristics or detailed information on prescription
dynamics at a patient level. Patient-level data can be used to assess
trends in use over time on a more detailed level, such as rates of
initiation of new prescriptions, discontinuation, or switching.
However, these data were not available for the present study. We
assessed a possible association between changes in Dutch and
British antidepressant use and media or regulatory warnings on a
national level, not on a micro level. Therefore, we used DDDs/
1000/day to present drug utilization patterns. One of the greatest
advantages of using the DDDs methodology when conducting
drug utilization studies is that it enables comparisons between
distinct molecules within and between countries. We consider that
the quality of our data, the quantity, and interpretation in DDDs,
were sufficient to answer our research question. However, further
research in this direction could focus on analyzing antidepressant
use and the influence of media and regulatory warnings at a
patient level as mentioned above. Another weakness of our study is
the lack of adjustment for pediatric doses. Unfortunately, the
DDD-methodology is limited to adults, since the standard value
assigned by the WHO is based on the main indication in adults.
The lack of adjustment in our results creates an underestimation of
the amount of antidepressant use in younger groups; this is
unavoidable for drug utilization studies when analyzing pediatric
off-label use. Unfortunately, due to the limited clinical evidence
about the use of antidepressants in children, and the fact that dose
calculations in children carry greater risks of error when compared
with adults (differences in age and weight), no standardized
guidelines for the use and dosage of antidepressants in children
have been developed to date [29,30]. Since we were interested in
Figure 2. SSRI use in the NL (A) and in the UK (B), segmentation of paroxetine in the NL (C) and in the UK (D). Dotted lines represent a
change in use trend and therefore a new, or the end of a segment. *The grey period illustrates the periods of media coverage of regulatory warnings.
doi:10.1371/journal.pone.0045515.g002
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the macro-level dynamics/patterns of antidepressant use in
children and the influence of media coverage of the warnings on
use, we decided to present pediatric antidepressant use in DDDs
despite all limitations. However, caution ought to be taken when
interpreting the absolute level of use (number of DDDs/1000/day)
in these young age groups.
The periods of media coverage of regulatory warnings had a
limited and temporal effect on overall SSRI use in both the UK
Figure 3. SSRI use in the NL through GPs (A) and specialists (B), segmentation of paroxetine use in the NL through GPs (C) and
specialists (D). Dotted lines represent a change in use trend and therefore a new, or the end of a segment. *The grey period illustrates the periods
of media coverage of regulatory warnings.
doi:10.1371/journal.pone.0045515.g003
Table 2. Number of DDD/1000 inhabitants/day of SSRIs in the Netherlands, and percentage between January 2000 and December
2009 stratified by medical specialty.
Specialty General Practitioner Specialists Unidentified
SSRI/Year 2000 2009 2000 2009 2000 2009
Citalopram 0.3 (2.2) 7.6 (32.8) 0.4 (12.5) 1.8 (35.9) 0.02 (7.1) 0.2 (52.4)
Escitalopram* 0.002 (0.0) 1.2 (5.3) 0.01 (0.5) 0.7 (13.8) 0.001 (0.3) 0.02 (6.5)
Fluoxetine 2.5 (18.8) 2.0 (8.6) 0.5 (16.6) 0.6 (11.6) 0.06 (17.3) 0.0 (6.3)
Fluvoxamine 1.6 (12.1) 1.1 (4.9) 0.4 (14.0) 0.2 (4.7) 0.03 (10.0) 0.0 (4.4)
Paroxetine 8.4 (62.8) 9.4 (40.2) 1.5 (44.8) 1.0 (19.0) 0.20 (59.5) 0.1 (21.7)
Sertraline 0.5 (4.0) 1.9 (8.3) 0.3 (10.5) 0.7 (14.9) 0.01 (4.4) 0.0 (9.6)
Total 13.3 (100) 23.3 (100) 3.1 (100) 5.0 (100) 0.33 (100) 0.4 (100)
Total (%) per
specialty
(79.5) (81.1) (18.5) (17.4) (2.0) (1.5)
*Data available from October 2004.
doi:10.1371/journal.pone.0045515.t002
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and NL. Significant reductions in SSRI use were not clearly
observed during these periods. Overall SSRI use doubled during
the period 2000–2010, which has been previously reported for
other countries as well [6,7,10,31–37]. It should be noted that
overall antidepressant use could have increased significantly in the
absence of regulatory actions or their coverage in the media, so the
full effect of the regulatory actions or their coverage in the media
may have been underestimated. When split by age groups, we
observed that the increasing trend for Dutch SSRI use was
temporarily interrupted in pediatrics, adolescents, and in less
intensity in adults after the first period of media coverage of the
warnings. Thereafter, SSRI use in these age groups recovered.
Contrarily, SSRI use consistently decreased in young adults,
whereas use by the elderly continued to increase despite media
coverage of the warnings. These temporal decreases in SSRI use
could indicate the prescribers’ attention and reaction to the
warnings or media coverage. A similar response from prescribers
to the regulatory advisories in children was reported for the UK,
albeit without evidence of media influence [38].
Recent research on prescribing behaviors in the UK demon-
strated that the increase in the prescriptions of antidepressants was
not attributed to an increase of new patients (initiation), but to an
increase in the number of long-term prescriptions [39]. Reasons
for this growth in long-term use of antidepressants are to prevent
relapses or recurrences, and to reduce the occurrence of
withdrawal symptoms by titration and maintenance dosing.
Research on antidepressant use in the NL in the 1990s
demonstrated a similar cumulative effect in use, namely an
increase in SSRI use both in terms of prevalence and incidence
[40]. During the 2000s, the Dutch Health Insurance Board
reported an increase in overall antidepressant use, while the
number of SSRI users remained constant [41], demonstrating a
shift in the 2000s when the prevalence of SSRI use increased, but
the incidence did not. All in all, changes in the management of
depression would be expected to affect population-level DDDs.
Although this cumulative effect on antidepressant use was reported
for both countries, UK national use was nearly two-fold higher
than in the NL despite the use of DDDs as equivalent measure.
Towards the end of our study period in 2008, two important
systematic reviews were published calling into question the
effectiveness of SSRIs not only in pediatrics, but in adults and
elderly, as well. In a meta-analysis, Kirsch et al. concluded that
antidepressants were no better than placebo, and that in more
severely depressed patients these drugs showed some effect, but
only because of a poor response to placebo [42]. In the second
publication, Turner et al. demonstrated that antidepressant trials
with positive outcomes were published more often that those
reporting negative outcomes [43]. This publication bias seemed to
provide an incomplete picture when analyzing the efficacy of
antidepressants by overestimating their efficacy. The publication
Figure 4. SSRI use in the NL in pediatrics (A), adolescents (B), young adults (C), and adults (D). *The grey period illustrates the period of
media coverage of regulatory warnings.
doi:10.1371/journal.pone.0045515.g004
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of both systematic reviews, in particular Kirsch et al., evoked
several media responses with controversial headers such as
‘‘depressing news, the happy pills don’t work’’, or ‘‘anti-
depressants taken by thousands of Brits ‘do NOT work’, major
new study reveals’’ [44,45]. Such publications, not related to the
safety controversy, may also influence SSRI use. Despite this
negative coverage in scientific journals and newspapers, SSRI use
remarkably continued to grow in both countries after 2008.
Overall SSRI growth in the UK was mainly driven by the use of
citalopram, escitalopram, and fluoxetine. The UK guideline
(NICE) for the treatment of depression recommends SSRIs, in
particular (es)citalopram and fluoxetine, as first-line pharmaco-
logical interventions for the treatment of mild to severe depression
based on their positive benefit/risk profile [46–48]. SSRIs growth
could be attributed to these recommendations and the prescribers’
compliance. Another factor that could have influenced the
increase in the use of escitalopram is its patented status (approved
in 2002). However, this was not the case for citalopram that
hitherto had shown a constant upward trend when its patent
expired in 2003. Contrary to citalopram, paroxetine use dropped
in February 2002, the same year that its patent status expired, and
prior to the first period of increased (negative) media coverage and
regulatory warnings. Most of the negative media coverage was
directed towards paroxetine in both the NL and UK. In 2001,
GlaxoSmithKline (GSK) lost its first lawsuit concerning paroxe-
tine’s association with murder and suicide [49,50], and this
resulted in a FDA product warning [51]. In 2002, the BBC aired a
documentary ‘The Secrets of Seroxat’ (paroxetine’s trademark)
that highlighted safety concerns about this product, both in terms
of suicidality and difficulties with discontinuing use [12]. These
series of events may have induced the plunge in paroxetine use in
the UK observed in our results prior to the first period of media
coverage of regulatory warnings, in February 2002.
Specific SSRI use in the NL was comparable with the UK to a
limited extent. Citalopram, escitalopram, and sertraline use also
showed upward trends in the period under survey, albeit with
limited signs of diminished use towards the end of the survey
period and after the periods of media coverage of regulatory
warnings. The Dutch GP guideline for the treatment of depression
in adults recommends either a TCA or an SSRI as first-line
treatment, giving priority to fluvoxamine, paroxetine, sertraline
and a lower priority to fluoxetine due to the long-half life [52].
Remarkably, individual SSRIs with a large market uptake and a
positive benefit/risk profile, such as citalopram and escitalopram
[46–48] are not mentioned, nor recommended in the Dutch
guidelines. The Dutch guideline for specialists extensively consid-
ers the benefits and risks of citalopram and escitalopram [53]. The
preference for paroxetine in GP guidelines may be one of many
factors why its use was less affected in the NL by media coverage of
regulatory warnings compared to the UK [52] where citalopram,
escitalopram, and fluoxetine are recommended for GP use. Most
of the SSRI prescriptions in the NL were issued by a GP (680%),
confirming previous research [54]. Dutch GPs and specialists
started prescribing less paroxetine towards the end of the first
period of media coverage of regulatory warnings, apparently
indicating a timely reaction from prescribers to the regulatory
advisories or media attention. On the other hand, the increasing
prescription rate of citalopram by both Dutch GPs and specialists
demonstrated little or no effect during both periods of media
coverage of regulatory warnings, as well as either prescribers’
disregard of the regulatory warnings or switching. The influence of
guidelines, reimbursement policies, and prescribing habits for
SSRI use should be further studied to better understand the
differences for specific SSRIs and between countries.
Notwithstanding the modest reduction in paroxetine use in the
NL, we measured significant drops in use for pediatrics, adolescents,
and young adults prior to the period of media coverage of regulatory
warnings. Therefore, no direct association between the periods of
media coverage of regulatory warnings and decreased paroxetine
use was found in young groups. Conversely, both periods of media
coverage of regulatory warning were associated with decreased
paroxetine use in adults and elderly, although the warnings (and
updates) were originally not thought to affect these age groups.
Presumably, disadvantages regarding the use of paroxetine, such as
the high risk of withdrawal effects or akathisia, could have caused
this reduction in use [55]. The first period of media coverage of
regulatory warnings (2003–2004) was associated with a temporal
dip in citalopram, and sertraline use in pediatrics, and adolescents in
NL. Similar reductions in SSRI use by children and adolescents
were also reported in other countries. [6,7,9,56–58]. However, our
data demonstrate that this temporal decrease in use by Dutch
children and adolescent user groups recovered between the first and
second period of media coverage of regulatory warnings. These
results may indicate that doctors outweighed the benefits of SSRIs
compared to the risks. Wijlaars et al. have reported similar long-
term use patterns for British children, but without systematically
accounting for the effects of the media coverage of the warnings, or
differential antidepressant use by various young age groups [38].
Conclusion
The timing of the media coverage of regulatory warnings about
the suicidality risk associated with SSRI use coincided with
changes in overall use in the NL and UK from 2000–2010. The
results of this study demonstrate that short-term investigations only
provide a snapshot of the potential implications of media coverage
and regulatory warnings. We confirmed a strong, but not causal,
association between periods of intense media coverage of
regulatory warnings and significant changes in SSRI use over a
ten-year period in both countries. However, our long-term
assessment illustrated that the changes were temporal, drug-
specific and more pronounced in pediatrics and young adults. The
twofold increase in SSRI use over the 10-year period indicates that
regulatory warnings and media coverage may come and go, but
they do not have a significant impact on the overall upward trend
of SSRI use as a drug class in both countries.
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